Validation of the French-Canadian version of the Expanded Prostate Cancer Index Composite (EPIC) in a French-Canadian population

  • Éric Vigneault CHU de Québec-Université Laval Research Center Department of Radiation Oncology, CHU de Québec-Université Laval
  • Josée Savard CHU de Québec-Université Laval Research Center Université Laval Cancer Research Centre School of Psychology, Université Laval
  • Marie-Hélène Savard CHU de Québec-Université Laval research center Université Laval Cancer Research Centre
  • Hans Ivers CHU de Québec-Université Laval Research Center Université Laval Cancer Research Centre School of Psychology, Université Laval
  • Philippe Després CHU de Québec-Université Laval Research Center Department of Radiation Oncology, CHU de Québec-Université Laval Université Laval Cancer Research Centre Département de physique, de génie physique et d’optique, Université Laval
  • William Foster Department of Radiation Oncology, CHU de Québec-Université Laval
  • André-Guy Martin CHU de Québec-Université Laval Research Center Department of Radiation Oncology, CHU de Québec-Université Laval
  • Vincent Fradet CHU de Québec-Université Laval Research Center Université Laval Cancer Research Centre Department of Surgery, Université Laval

Abstract

Introduction: This study aims to empirically validate the French- Canadian version of the Expanded Prostate Cancer Index Composite (EPIC), a measure of health-related quality of life for prostate cancer patients.

Methods: Two hundred fifty-one participants completed a battery of self-report scales, including the French-Canadian version of the EPIC, after having received radiation therapy or radical prostatectomy for prostate cancer.

Results: The internal consistency for the urinary incontinence, bowel, and sexual domains of the EPIC-26 was high (Cronbach’s alpha coefficients from 0.80‒0.92), while coefficients for the urinary irritation/obstruction (0.59) and hormonal (0.67) domains were lower. Item-total correlations (rs=0.15‒0.85), and temporal stability (rs=0.72‒0.93) generally supported the reliability of the instrument. The five-factor structure of the EPIC-26 was confirmed for the most part. The construct validity of the instrument was also supported by high correlations obtained between each domain and measures assessing similar constructs (rs=-0.56‒0.83). The EPIC also showed an excellent sensitivity to change with significant differences obtained on EPIC scores (all p<0.05) between pre- and post-prostate cancer treatment.

Conclusions: The psychometric qualities of the French-Canadian version of the EPIC are well-supported, thus providing a valid tool to assess health-related quality of life in prostate cancer patients.

Published
2017-11-01
How to Cite
Vigneault, Éric, Savard, J., Savard, M.-H., Ivers, H., Després, P., Foster, W., Martin, A.-G., & Fradet, V. (2017). Validation of the French-Canadian version of the Expanded Prostate Cancer Index Composite (EPIC) in a French-Canadian population. Canadian Urological Association Journal, 11(12), 404-10. https://doi.org/10.5489/cuaj.4428
Section
Original Research